Product Code: 978-1-68038-443-7
Personalized Medicine Market Growth & Trends:
The global personalized medicine market size is expected to reach USD 922.72 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 6.95% from 2022 to 2030 owing to the increasing incidence of diseases and the rising demand for novel therapeutic drugs. The emerging applications of personalized medicine are consistently enhanced by immense research efforts. For instance, in July 2022, researchers at the UMass Chan Medical School developed a microorganism-based personalized medicine model system to aid the understanding of variation in metabolism to gauge the connection between an individual's genome, diet, microbiota, and associative environmental factors.
Most cancer conditions are usually caused by an underlying genetic discrepancy and can cause fatalities with progression. The cancer condition can be effectively and precisely treated by understanding specific genomic characteristics. For instance, in May 2020, Qiagen launched QIAseq pan-cancer multi-modal panel to enable robust analysis of genomic characteristics of cancer subjects to derive a broad spectrum of applications in precision medicine for the profiling of solid tumors and heme malignancies.
The market is positively driven by advancements in NGS technologies and extensive research on the human genome. There has been an increasing focus on utilizing NGS to derive personalized medicine outcomes that could potentially be used for the treatment of cancer and rare genetic disorders. For instance, Illumina declared that it will present its multiple oncology research abstracts at the European Society of Medical Oncology (ESMO) annual meeting in Paris. Their research enables personalized cancer care using comprehensive genomic profiling of biopsies to match subjects to the potential drugs and immunotherapies.
Telemedicine facilitates virtual or telephonic clinical advice to aid physical convenience. Telemedicine is increasingly trending, especially after the COVID-19 pandemic. Government and research institutes are taking substantial efforts to enhance the applications of personalized telemedicine. For instance, in August 2022, the National Cancer Institute declared a grant of USD 23 million for five years to aid the launch of Telehealth Research Centers of Excellence (TRACE) across the U.S. The program was launched with the support of the White House Cancer Moonshot to seek development and advancements in telehealth delivery for cancer care with a mission to leverage health equity.
Molecular imaging systems and medical devices are playing a primary role in emerging advancements in personalized medicine. They effectively leverage the applications of personalized medicine in the treatment of different types of cancers. For instance, in June 2022, GE Healthcare declared the release of high-end molecular imaging by using gallium-68 radioisotope for the diagnosis and monitoring of prostate cancer so as to leverage access to precision health and theranostics for personalized prostate cancer treatment at an early stage of cancer progression.
The market is in the growth phase due to emerging technological advancements along with consistent industrial efforts such as collaborations and expansions. For instance, in December 2021, Biogen Inc., and TheraPanacea declared that they have signed a collaboration that focuses on advancing digital health for personalized medicine in neuroscience.
Personalized Medicine Market Report Highlights:
- The overall growth of the market is attributed to the rising need for novel therapeutic drugs coupled with leveraged genetic level understanding of diseases and the rising incidence of cancers and genetic disorders across the globe
- The personalized medicine therapeutics segment is anticipated to witness high growth over the forecast period owing to the extensive usage of pharmacogenomics for developing biopharmaceuticals. Further, the genomic medicine therapeutics segment is anticipated to grow substantially during the forecast period owing to significantly lowered costs of whole-genome sequencing
- North America dominated the market in 2021 due to the presence of key players and their intensive research for the development of novel therapies to find out curative solutions for various diseases
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Research Scope
- 1.1.1 Estimates and Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Objectives
- 1.6.1 Objective 1
- 1.6.2 Objective 2
Chapter 2 Executive Summary
- 2.1 Personalized Medicine Market: Market Outlook
Chapter 3 Market Variables, Trends & Scope
- 3.1 Market Trends & Outlook
- 3.2 Trend Analysis
- 3.2.1 Product Trends
- 3.2.1.1 Personalized Medicine Diagnostics Trends
- 3.2.1.2 Personalized Medicine Therapeutics Trends
- 3.2.1.3 Personalized Medical Care Trends
- 3.2.1.4 Personalized Nutrition & Wellness Trends
- 3.3 Market Segmentation & Scope
- 3.4 Market Dynamics
- 3.4.1 Market driver analysis
- 3.4.1.1 Utility of human genome data for clinical research
- 3.4.1.1.1Targeted and personalized healthcare
- 3.4.1.2 Technological advancements to facilitate R&D for Personalized Medicine
- 3.4.1.2.1 Emergence of advanced genome editing techniques
- 3.4.1.2.2 Utility of novel databases for research
- 3.4.2 Market restraint analysis
- 3.4.2.1 Ethical issues and protection of individual's genomic data
- 3.4.2.2 Limited access to human genome data and databases
- 3.4.3 Opportunity analysis
- 3.5 Impact of COVID - 19 Pandemic on Personalized Medicine Market
- 3.6 Penetration & Growth Prospect Mapping for Products, 2021
- 3.7 Business Environment Analysis
- 3.7.1 Personalized Medicine Market - Swot Analysis, By Factor (Political & Legal, Economic And Technological)
- 3.7.2 Porter's Five Forces Analysis
- 3.8 Market Share Analysis
- 3.8.1 Company Size
- 3.8.2 Product portfolio
- 3.8.3 Strategic Initiatives
- 3.9 Competitive Landscape
- 3.9.1 Strategy Framework
- 3.9.2 Market Participation Categorization
- 3.9.2.1 New/ emerging entrants
- 3.9.2.2 Mature players & leaders
Chapter 4 Product Business Analysis
- 4.1 Personalized Medicine Diagnostics
- 4.1.1 Global Personalized Medicine Diagnostics Market, 2018 - 2030 (USD Billion)
- 4.1.2 Genetic Testing
- 4.1.2.1 Global Personalized Medicine Market for Genetic Testing, 2018 - 2030 (USD Billion)
- 4.1.3 Direct - To - Consumer (DTC) Testing
- 4.1.3.1 Global Personalized Medicine Market for Direct - To - Consumer (DTC) Testing, 2018 - 2030 (USD Billion)
- 4.1.4 Esoteric Lab Services
- 4.1.4.1 Global Personalized Medicine Market for Esoteric Lab Services, 2018 - 2030 (USD Billion)
- 4.1.5 Esoteric Lab Tests
- 4.1.5.1 Global Personalized Medicine Market for Esoteric Lab Services, 2018 - 2030 (USD Billion)
- 4.2 Personalized Medicine Therapeutics
- 4.2.1 Global Personalized Medicine TherapeuticsMarket, 2018 - 2030 (USD Billion)
- 4.2.2 Pharmaceuticals
- 4.1.2.1 Global Personalized Therapeutics Market for Pharmaceuticals, 2018 - 2030 (USD Billion)
- 4.1.3 Genomic Medicine
- 4.1.3.1 Global Personalized Therapeutics Market for Genomic Medicine, 2018 - 2030 (USD Billion)
- 4.1.4 Medical Devices
- 4.1.4.1 Global Personalized TherapeuticsMarket for Medical Devices, 2018 - 2030 (USD Billion)
- 4.3 Personalized Medical Care
- 4.2.1 Global Personalized Medical CareMarket, 2018 - 2030 (USD Billion)
- 4.2.2 Telemedicine
- 4.1.2.1 Global Personalized Medical Care Market for Telemedicine, 2018 - 2030 (USD Billion)
- 4.1.3 Health Information Technology
- 4.1.3.1 Global Personalized Medical Care Market for Health Information Technology, 2018 - 2030 (USD Billion)
- 4.3 Personalized Nutrition & Wellness
- 4.2.1 Global Personalized Nutrition & WellnessMarket, 2018 - 2030 (USD Billion)
- 4.2.2 Retail Nutrition
- 4.1.2.1 Global Nutrition & Wellness Market for Retail Nutrition, 2018 - 2030 (USD Billion)
- 4.1.3 Complementary & Alternative Medicine
- 4.1.3.1 Global Nutrition & Wellness Market for Complementary & Alternative Medicine, 2018 - 2030 (USD Billion)
Chapter 5 Regional Business Analysis
- 5.1Persoanlized Medicine Market: Regional Movement Analysis, 2021 & 2030
- 5.2 North America
- 5.2.1 North America market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.2.2 U.S.
- 5.2.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.2.3 Canada
- 5.2.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.3 Europe
- 5.3.1 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.3.2 Germany
- 5.3.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.3.3 U.K.
- 5.3.3.1 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.3.4 France
- 5.3.4.1 France market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.3.5 Italy
- 5.3.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.3.6 Spain
- 5.3.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.4.2 Japan
- 5.4.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.4.3 China
- 5.4.3.1 China market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.4.4 India
- 5.4.4.1 India market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.4.5 Australia
- 5.4.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.4.6 South Korea
- 5.4.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.5 Latin America (LATAM)
- 5.5.1 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.5.2 Brazil
- 5.5.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.5.3 Mexico
- 5.5.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.5.4 Argentina
- 5.5.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.6 Middle East and Africa (MEA)
- 5.6.1 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.6.2 South Africa
- 5.6.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.6.3 Saudi Arabia
- 5.6.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.6.4 UAE
- 5.6.4.1 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 6 Company Profiles
- 6.1 Company Profiles
- 6.1.1 GE Healthcare
- 6.1.1.1 Company Overview
- 6.1.1.2 Financial Performance
- 6.1.1.3 Product Benchmarking
- 6.1.1.4 Strategic Initiatives
- 6.1.2 Illumina, Inc.
- 6.1.2.1 Company Overview
- 6.1.2.2 Financial Performance
- 6.1.2.3 Product Benchmarking
- 6.1.2.4 Strategic Initiatives
- 6.1.3 ASURAGEN, INC.
- 6.1.3.1 Company Overview
- 6.1.3.2 Financial Performance
- 6.1.3.3 Product Benchmarking
- 6.1.3.4 Strategic Initiatives
- 6.1.4 Abbott
- 6.1.4.1 Company Overview
- 6.1.4.2 Financial Performance
- 6.1.4.3 Product Benchmarking
- 6.1.4.4 Strategic Initiatives
- 6.1.5 Dako A/S
- 6.1.5.1 Company Overview
- 6.1.5.2 Financial Performance
- 6.1.5.3 Product Benchmarking
- 6.1.5.4 Strategic Initiatives
- 6.1.6 Exact Sciences Corporation
- 6.1.6.1 Company Overview
- 6.1.6.1 Financial Performance
- 6.1.6.2 Product Benchmarking
- 6.1.6.3 Strategic Initiatives
- 6.1.7 Cepheid, Inc. (Danaher Corporation)
- 6.1.7.1 Company Overview
- 6.1.7.2 Financial Performance
- 6.1.7.3 Product Benchmarking
- 6.1.7.4 Strategic Initiatives
- 6.1.8 Decode Genetics, Inc.
- 6.1.8.1 Company Overview
- 6.1.8.2 Financial Performance
- 6.1.8.3 Product Benchmarking
- 6.1.8.4 Strategic Initiatives
- 6.1.9 QIAGEN, Inc.
- 6.1.9.1 Company Overview
- 6.1.9.2 Financial Performance
- 6.1.9.3 Product Benchmarking
- 6.1.9.4 Strategic Initiatives
- 6.1.10 Exagen Inc.
- 6.1.10.1 Company Overview
- 6.1.10.2 Financial Performance
- 6.1.10.3 Product Benchmarking
- 6.1.10.4 Strategic Initiatives
- 6.1.11 Precision Biologics
- 6.1.11.1 Company Overview
- 6.1.11.2 Financial Performance
- 6.1.11.3 Product Benchmarking
- 6.1.11.4 Strategic Initiatives
- 6.1.12 Celera Diagnostics LLC
- 6.1.12.1 Company Overview
- 6.1.12.2 Financial Performance
- 6.1.12.3 Product Benchmarking
- 6.1.12.4 Strategic Initiatives
- 6.1.13 Biogen
- 6.1.13.1 Company Overview
- 6.1.13.2 Financial Performance
- 6.1.13.3 Product Benchmarking
- 6.1.13.4 Strategic Initiatives
- 6.1.14 Genelex (Invitae Corporation)
- 6.1.14.1 Company Overview
- 6.1.14.2 Financial Performance
- 6.1.14.3 Product Benchmarking
- 6.1.14.4 Strategic Initiatives
- 6.1.15 International Business Machines Corporation (IBM)
- 6.1.15.1 Company Overview
- 6.1.15.2 Product Benchmarking
- 6.1.15.3 Strategic Initiatives
- 6.1.16 Genentech, Inc.
- 6.1.16.1 Company Overview
- 6.1.16.2 Financial Performance
- 6.1.16.3 Product Benchmarking
- 6.1.16.4 Strategic Initiatives
- 6.1.17 23 andMe, Inc.
- 6.1.17.1 Company Overview
- 6.1.17.2 Financial Performance
- 6.1.17.3 Product Benchmarking
- 6.1.17.4 Strategic Initiatives